management of cll progression after ibrutinib
Published 4 years ago • 1.5K plays • Length 4:07Download video MP4
Download video MP3
Similar videos
-
4:22
progression on frontline ibrutinib in cll
-
1:21
evolving management of relapsed cll: uk cll forum analysis of ibrutinib at first relapse
-
20:40
cll: treatment for btki progressors
-
25:38
cll: chemotherapy and ibrutinib based regimens
-
5:04
cll: post-ibrutinib or chemoimmunotherapy approaches
-
2:43
outcomes in high-risk cll patients following fixed-duration treatment with ibrutinib plus venetoclax
-
29:14
ibrutinib resistance-mechanisms and options in cll
-
2:01
the evolution of bcl2 inhibition in cll
-
1:37
acalabrutinib may be an alternative to ibrutinib for treatment of cll
-
1:09
dr. chanan-khan on ibrutinib as backbone of treatment for cll
-
6:07
cll: the biologics of ibrutinib therapy
-
5:19
additional insights: management of ibrutinib in cll
-
5:09
second-line options in cll: progressing on ibrutinib
-
59:17
chronic lymphocytic leukemia (cll) - diagnosis, prognosis and management with ibrutinib
-
7:05
stopping ibrutinib therapy for cll after 6 years
-
1:56
ibrutinib plus venetoclax for first-line treatment of cll: 4-year follow-up data
-
7:13
using ibrutinib in chronic lymphocytic leukemia (cll)
-
9:02
efficacy and future role of ibrutinib in cll and mcl
-
2:22
treating patients with cll who progress after btk inhibitor therapy